Glimy-MP 2 Tablet SR is a combination oral hypoglycemic agent containing Glimepiride 2mg, Metformin 500mg, and Pioglitazone 15mg, formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which modulates the transcription of insulin-responsive genes involved in glucose and lipid metabolism. The sustained-release formulation ensures a gradual release of active ingredients, promoting stable plasma concentrations and reducing dosing frequency, thereby enhancing patient compliance. Glimy-MP 2 is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes inadequately controlled on monotherapy or dual therapy. Caution is advised in patients with hepatic or renal impairment, heart failure, or a history of lactic acidosis. Regular monitoring of blood glucose, liver function, and cardiovascular status is recommended during therapy. This combination therapy offers a multifaceted approach to managing hyperglycemia by targeting different pathophysiological defects in type 2 diabetes.